Sun Pharmaceutical Industries Ltd
Add to watch list to get report alerts
BSE Code:
524715
NSE Code:
SUNPHARMA*
Business Profile
Business Profile
Sun Pharma (SUNPHARMA) is into specialty pharmaceuticals and active pharmaceutical ingredients. The company operates in select therapeutic segments like psychiatry, neurology, cardiology and gastroenterology. As many as eight bulk actives and 18 processes for DMFs have been developed and scaled up. In all, the company has received seven DMFs and nine EDMFs.
The company doubled its capacity and the area at the bulk active site in Panoli. With the completion of this expansion, 269,000 sq. ft. area has been added to the plant thereby offering additional 129 KL reactor capacity for the regulated markets.
The company plans to work on various technologies in NDDS and work on specific therapy areas for NCE. For products that are differentiated for the medium term, it would continue to work on technologically complex products such as liposome delivery systems, microspheres based delivery systems and controlled release technologies.
Financials
Sun Pharmaceutical Industries registered a 34.33% growth in net profits to Rs 1,556.70 million for the quarter ended in March, 2007 from Rs 1,158.90 million for the quarter ended in March, 2006Net Sales rose 2.87% to Rs 4,306.40 million for the quarter ended March, 2007 compared with Rs 4,186.30 million for the quarter ended March, 2006.Total income rose 39.46% to Rs 6,337.4 million in the quarter ended March, 2007, from Rs 4,544.3 million for the quarter ended March, 2006.The earnings per share (EPS) of the company stood at Rs 8.10 in the quarter ended March, 2007.
Recent Developments
07-MAY-09
The company`s arm has been granted a tentative approval from USFDA for its Abbreviated New Drug Application (ANDA) for generic Uroxatral Extended Release tablets.
27-APR-09
The company`s US arm has obtained a final approval from US Food and Drug Administration (USFDA) to market Bethanechol Chloride tablet on prescription basis.
13-APR-09
US Food and Drug Administration (USFDA) has granted the company`s subsidiary an approval for its abbreviated new drug application (ANDA) to market generic Roxicodone, oxycodone hydrochloride tablets.
07-JAN-09
The company along with its subsidiaries received final approval from US Food and Drug Administration (USFDA) for several abbreviated new drug applications (ANDA).